News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Vaxon-Biotech Announces Phase I Study Results for VX-001 Immunotherapy In Cancer Patients


10/19/2005 5:12:24 PM

Vaxon-Biotech today announces that it has completed the phase I trial of its candidate vaccine VX-001. The trial was conducted at Heraklion University Hospital in Greece. VX-001 was well-tolerated, stimulated T-cell immunity, and continues to show clinical benefits in participating patients.


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES